Loading stock data…
Adaptive Biotechnologies Corpor (ADPT)
$24.34+0.06 (+0.25%)
After Hours$24.34+0.00 (+0.00%)· Last close Sep 8
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Adaptive Biotechnologies Corporation in the Healthcare sector is trading at $24.34 with a market capitalization of $4.0B. Wall Street consensus targets $25.07 (7 analysts), implying a +3.0% move over the next 12 months. The stock is currently near its 52-week high of $26.87, remaining 37.2% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side consensus broadly in line with current price
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | — | $70.87M↓ | $71.68M↓ | $93.97M↑ | $58.88M |
| Gross Profit | — | $52.17M↓ | $53.46M↓ | $75.82M↑ | $40.88M |
| Operating Income | — | -$19.21M↓ | -$12.77M↓ | $10.29M↑ | -$25.04M |
| Net Income | — | -$20.03M↓ | -$13.58M↓ | $9.55M↑ | -$25.61M |
Peer Comparison
JNJUNHPFE
Fundamentals
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$4.02B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.09
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-11.12%
Volume
Today's trading volume
1.36M
Recent News
What Is Really Moving Tempus AI Stock Right Now?
While traders pointed to external clinical-trial momentum as a major catalyst, Tempus's own recent guidance raise and narrowing losses provided the underlying backdrop.
Adaptive Biotechnologies Stock Has Doubled in the Past Year. Here’s What Could Come Next.
Adaptive Biotechnologies (ADPT) has surged 100% over the past year, driven by strong technical momentum. Shares recently hit a new 3-year high. Analyst sentiment is mixed with price targets ranging from $17 to $30. Investor focus has shifted from ADPT’s technology to its business execution, with technical indicators and momentum...
Adaptive Biotechnologies Corp (ADPT) (Q2 2026) Earnings Call Highlights: MRD Revenue Surges ...
Adaptive Biotechnologies Corp (ADPT) reports a strong Q2 with MRD revenue up 49% (ex-milestones) and raises full-year guidance, while progressing the separation of its Immune Medicine business.
Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates
Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?